Clinical

Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the placebo effect seen in clinical trials of chronic cough treatment.

This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.

Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.

Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.

In patients with liver involvement, intrahepatic cholangiocarcinoma was a common diagnosis among some patients with cancer of unknown primary (CUP).

Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting improvements in clinical outcomes.

Medication dose captures modification of hypertension treatment intensity more precisely than medication count, and this measure should be preferred in studies that aim to improve hypertension management.

The proportion of colonoscopies performed for postpolypectomy surveillance has increased significantly, particularly among older patients with limited life expectancy, raising concern for possible overuse.

Among patients with rheumatoid arthritis (RA) in clinical remission, patient-physician discordance when assessing disease activity may be associated with the inability to achieve remission.

Dr Eliot Brinton elaborates on unmet needs in lipid management and how they can be remedied.

Ian Riddock, MD, and Leandro N. Slipczuk, MD, PhD, discuss the importance of LDL-C management as part of the discharge plan for patients, as well as ensuring continuity of care from the inpatient to outpatient setting.

Of the 5800 patients included in study, 20% were Black, which the researchers say adequately represents disease incidence among the population.

Among the fewer than half of patients with cancer who received opioid fills, a relatively small proportion (2.5%) had potentially problematic opioid use.

Although classic methods of risk stratification still hold value, the authors said genetic analysis holds significant promise.

The study showed that introducing the TLR7 variant in an animal model led to the development of autoimmune symptoms and potential development of systemic lupus erythematosus (SLE).

Fidaxomicin, now commonly used to treat Clostridioides difficile infection, selectively targets the bacterium while sparing crucial gut commensals that protect against colonization. However, knowledge gaps in the molecular basis of its narrow-spectrum activity remain.

A new review article summarizes current approaches to precision medicine in lung cancer.

While risk factors for pterygia are well-known, the underlying disease mechanisms have not been fully clarified in past studies. A new analysis using RNA sequencing pinpointed ptergyia-specific biomarkers and potential therapeutic targets.

Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete response at 100 days.

Among a group of patients with lung cancer who were not suitable for anticancer treatment, the researchers found that 40% underwent additional investigations after their initial CT scan before eventually receiving best supportive care.

Not only did a majority of each group say they hadn’t heard of biosimilars, but those who had heard of them had negative perceptions.

Within 4 weeks of starting treatment, patients experienced improvements in their condition, indicating an anti-inflammatory effect of the treatment.

Kevin Stephens, Sr. MD, JD examines key drivers of healthcare utilization for women of childbearing years.

Steven McCarus, MD FACOG highlights the shift away from surgical treatment toward medical therapy in UF and endometriosis.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.

A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).

This systematic review and meta-analysis used a literature search to gather data from long-term randomized controlled trials on the effectiveness of closed-loop insulin systems (CLS) among nonpregnant patients with type 1 diabetes (T1D).

In this new subanalysis of data from the Atherosclerosis Risk in the Communities study, investigators assessed the risk of incident heart failure (HF) or death by race and sex, as influenced by N-terminal pro–B-type natriuretic peptide (NT-proBNP) concentration, prompted by growing interest in its use as a predictive biomarker for HF.